J Cell Biol:樊代明院士发现miR-7可抑制胃癌的发展

2015-08-12 sunshine 译 MedSci原创

据发表于Cell Biology 的一项研究表明,Cell Biology miR-7可通过抑制一个关键的信号通道以抑制胃癌的发生,而且这种保护机制可被致癌细菌幽门螺杆菌所损害。因此,发现能够诱导miR-7的药物可因此成为抑制胃癌发展的一项有效的治疗手段。据美国国立卫生研究院称,胃癌是全球第四大常见的癌症,且是癌症相关死亡的第三大原因。常在胃癌中表达降低的miR-7可通过抑制特定生长因子受体(IG


据发表于J Cell Biology 的一项研究表明,Cell Biology miR-7可通过抑制一个关键的信号通道以抑制胃癌的发生,而且这种保护机制可被致癌细菌幽门螺杆菌所损害。

因此,发现能够诱导miR-7的药物可因此成为抑制胃癌发展的一项有效的治疗手段。

据美国国立卫生研究院称,胃癌是全球第四大常见的癌症,且是癌症相关死亡的第三大原因。常在胃癌中表达降低的miR-7可通过抑制特定生长因子受体(IGF1R)阻止癌细胞扩散至其他组织。然而,miR-7是否也可抑制胃癌的早期阶段尚未可知,因此中国的研究员筛查了microRNA的新靶点。

Dai-Ming Fan及其同事发现miR-7的直接靶向基因-RELA 及FOS基因,该基因可分别编码参与原癌基因NF-κB 及AP-1信号通路的蛋白质。在人类胃癌标本中,低水平的miR-7与RELA及FOS蛋白的水平升高及患者生存率较低有关。小鼠实验研究发现,miR-7的水平升高可降低RELA 及FOS的水平并抑制肿瘤生长。

研究人员发现,除可直接抑制RELA的表达外,miR-7还可通过在NF-κB信号通路中靶向作用于其上游激酶(IKKε)以控制蛋白质的活化。然而,这一相同的通路本身可抑制miR-7的表达,表明了如果NF-κB通路被强烈激活,那么miR-7将无法抑制RELA的活性。

慢性幽门螺旋杆菌感染是胃癌发生的主要危险因素,部分是由于该细菌可以过度激活NF-κB通路。因此,Fan及其同事发现将幽门螺旋杆菌与胃细胞共同培养可激活IKKε及RELA,并减少miR-7的表达,这是正常胃细胞转化为癌细胞关键步骤。

原始出处:

miR-7 suppresses stomach cancer.MNT, 11 August 2015.

Zhao, X.-D., et al.MicroRNA-7/NF-κB signaling regulatory feedback circuit regulates gastric carcinogenesis J. Cell Biol. 2015.doi: 10.1083/jcb.201501073

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869183, encodeId=966f186918381, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 29 22:45:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917184, encodeId=09b4191e18464, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 20 16:45:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930419, encodeId=b0e6193041976, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 01 16:45:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57780, encodeId=be6b5e7808c, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57781, encodeId=dd735e78133, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57782, encodeId=2bf75e78292, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57783, encodeId=38555e783a7, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57778, encodeId=0e145e77814, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57779, encodeId=44375e7794b, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766958, encodeId=9c981e6695820, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Aug 18 20:45:00 CST 2015, time=2015-08-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869183, encodeId=966f186918381, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 29 22:45:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917184, encodeId=09b4191e18464, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 20 16:45:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930419, encodeId=b0e6193041976, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 01 16:45:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57780, encodeId=be6b5e7808c, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57781, encodeId=dd735e78133, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57782, encodeId=2bf75e78292, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57783, encodeId=38555e783a7, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57778, encodeId=0e145e77814, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57779, encodeId=44375e7794b, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766958, encodeId=9c981e6695820, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Aug 18 20:45:00 CST 2015, time=2015-08-18, status=1, ipAttribution=)]
    2016-06-20 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869183, encodeId=966f186918381, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 29 22:45:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917184, encodeId=09b4191e18464, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 20 16:45:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930419, encodeId=b0e6193041976, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 01 16:45:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57780, encodeId=be6b5e7808c, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57781, encodeId=dd735e78133, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57782, encodeId=2bf75e78292, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57783, encodeId=38555e783a7, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57778, encodeId=0e145e77814, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57779, encodeId=44375e7794b, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766958, encodeId=9c981e6695820, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Aug 18 20:45:00 CST 2015, time=2015-08-18, status=1, ipAttribution=)]
    2015-12-01 heli0118
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869183, encodeId=966f186918381, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 29 22:45:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917184, encodeId=09b4191e18464, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 20 16:45:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930419, encodeId=b0e6193041976, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 01 16:45:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57780, encodeId=be6b5e7808c, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57781, encodeId=dd735e78133, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57782, encodeId=2bf75e78292, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57783, encodeId=38555e783a7, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57778, encodeId=0e145e77814, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57779, encodeId=44375e7794b, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766958, encodeId=9c981e6695820, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Aug 18 20:45:00 CST 2015, time=2015-08-18, status=1, ipAttribution=)]
    2016-01-16 medsic

    希望能研制出这种药,来为临床再做贡献,

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1869183, encodeId=966f186918381, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 29 22:45:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917184, encodeId=09b4191e18464, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 20 16:45:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930419, encodeId=b0e6193041976, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 01 16:45:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57780, encodeId=be6b5e7808c, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57781, encodeId=dd735e78133, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57782, encodeId=2bf75e78292, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57783, encodeId=38555e783a7, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57778, encodeId=0e145e77814, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57779, encodeId=44375e7794b, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766958, encodeId=9c981e6695820, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Aug 18 20:45:00 CST 2015, time=2015-08-18, status=1, ipAttribution=)]
    2016-01-16 medsic

    希望能研制出这种药,来为临床再做贡献,

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1869183, encodeId=966f186918381, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 29 22:45:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917184, encodeId=09b4191e18464, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 20 16:45:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930419, encodeId=b0e6193041976, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 01 16:45:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57780, encodeId=be6b5e7808c, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57781, encodeId=dd735e78133, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57782, encodeId=2bf75e78292, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57783, encodeId=38555e783a7, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57778, encodeId=0e145e77814, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57779, encodeId=44375e7794b, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766958, encodeId=9c981e6695820, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Aug 18 20:45:00 CST 2015, time=2015-08-18, status=1, ipAttribution=)]
    2016-01-16 medsic

    赞!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1869183, encodeId=966f186918381, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 29 22:45:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917184, encodeId=09b4191e18464, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 20 16:45:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930419, encodeId=b0e6193041976, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 01 16:45:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57780, encodeId=be6b5e7808c, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57781, encodeId=dd735e78133, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57782, encodeId=2bf75e78292, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57783, encodeId=38555e783a7, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57778, encodeId=0e145e77814, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57779, encodeId=44375e7794b, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766958, encodeId=9c981e6695820, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Aug 18 20:45:00 CST 2015, time=2015-08-18, status=1, ipAttribution=)]
    2016-01-16 medsic

    赞!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1869183, encodeId=966f186918381, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 29 22:45:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917184, encodeId=09b4191e18464, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 20 16:45:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930419, encodeId=b0e6193041976, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 01 16:45:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57780, encodeId=be6b5e7808c, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57781, encodeId=dd735e78133, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57782, encodeId=2bf75e78292, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57783, encodeId=38555e783a7, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57778, encodeId=0e145e77814, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57779, encodeId=44375e7794b, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766958, encodeId=9c981e6695820, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Aug 18 20:45:00 CST 2015, time=2015-08-18, status=1, ipAttribution=)]
    2016-01-16 medsic

    嗯,好消息,

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1869183, encodeId=966f186918381, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 29 22:45:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917184, encodeId=09b4191e18464, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 20 16:45:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930419, encodeId=b0e6193041976, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 01 16:45:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57780, encodeId=be6b5e7808c, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57781, encodeId=dd735e78133, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57782, encodeId=2bf75e78292, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57783, encodeId=38555e783a7, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57778, encodeId=0e145e77814, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57779, encodeId=44375e7794b, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766958, encodeId=9c981e6695820, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Aug 18 20:45:00 CST 2015, time=2015-08-18, status=1, ipAttribution=)]
    2016-01-16 medsic

    嗯,好消息,

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1869183, encodeId=966f186918381, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 29 22:45:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917184, encodeId=09b4191e18464, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 20 16:45:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930419, encodeId=b0e6193041976, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 01 16:45:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57780, encodeId=be6b5e7808c, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57781, encodeId=dd735e78133, content=希望能研制出这种药,来为临床再做贡献,, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57782, encodeId=2bf75e78292, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57783, encodeId=38555e783a7, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:35:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57778, encodeId=0e145e77814, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57779, encodeId=44375e7794b, content=嗯,好消息,, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:34:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766958, encodeId=9c981e6695820, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Aug 18 20:45:00 CST 2015, time=2015-08-18, status=1, ipAttribution=)]

相关资讯

非侵入式癌症诊断

新加坡的研究人员研发出一种于非侵入式胃癌检测的方法,利用一种指示癌症存在的mico-RNA,灵敏度超高。 2012年,世界范围内共有820万人死于癌症,这个数字预计2030年翻倍。其实,如果疾病能更早得到诊断,很多癌症死亡病例都可以避免。 为改善癌症检测状况,新加坡研究人员研发了一种非侵入式的肿瘤诊断方法,其实质是检测在基因表达调节起到重要作用的一类非编码RNA分子micro-RNA(miRN

Surgery:胃癌D1+术式能取代D2?

早在 1960年日本开始推荐 D2淋巴结廓清术(D1+和 10,11d,12a)是治疗胃癌的标准术式;而且一直以来 D2淋巴结廓清术被认为可以提高患者预后,但同时却也提高了术后并发症和死亡率,这主要是由于术中为了完成 10和 11d淋巴结的清扫而切除了脾脏和远端胰腺的缘故(同样加重了手术的困难)。另外,术中难于施行肝固有动脉处 12a组淋巴结的清除,故 12a组淋巴结对肿瘤的影响还没有完全阐述清楚

Cochrane DB Syst Rev:根除幽门螺杆菌可有效减小胃癌的发生危险

最新研究显示使用短程药物根除最为常见的幽门螺杆菌可降低胃癌的发生风险,该研究成果在线发表于 Cochrane Database of Systematic Reviews 。幽门螺杆菌存在三分之二的人群中,是胃溃疡发生的主要原因,但是多数人并没有自觉症状。“该次系统性回顾的发现再次为越来越多认为根除幽门螺杆菌可预防普通人群胃癌的发生这一观点提供了证据,”该研究的共同作者 Dr. Paul Moay

Gut:呼气式胃癌检测准确率可达92%

科学家们正在研发一种分析人类呼出气体的技术。在不久的未来,我们可以在几分钟之内通过分析呼出气体判断一个人是否患上了胃癌。 我们每天呼出和呼进的分子有其独特的组成模式,而这能够反映人体的健康情况。因此,科学家试图利用检测技术将人们的呼吸情况“打印出来”。实际上,我们已经研发出了与其相类似的技术检测其他类型的癌症。不过科学家表示分析呼吸情况对于检测胃癌而言意义重大,因为这种疾病在西方

Scientific Reports:Sirt7抑制凋亡促胃癌发展

近日,国际学术期刊scientific reports在线发表了中国科学家关于组蛋白去乙酰化酶sirt7在胃癌中具体作用的最新科研进展,他们发现sirt7对胃癌发展具有重要促进作用,而这种促癌作用主要是通过sirt7的组蛋白去乙酰化酶功能影响具有抗癌作用的microRNA-34a的表达实现的。胃癌在全球最常见的癌症中排名第四,胃癌病人的5年生存率非常低。之前研究发现表观遗传修饰在胃癌发展中具有重要

Biochem J:DDB2调控PAQR3影响胃癌转移和增殖

6月11日,国际学术期刊Biochemical Journal在线发表了中科院上海生科院营养科学研究所陈雁研究组的研究论文“DDB2 is involved in ubiquitination and degradation of PAQR3 and regulates tumorigenesis of gastric cancer cells”,该研究揭示了DDB2通过参与PAQR3的泛素化降解